Atropine Eye Drops: An Effective Tool in Myopia Management

If your child has myopia, you probably already know about glasses and contact lenses. There is another option: atropine eye drops. These drops have been used for a long time to slow the progression of myopia. They are not a cure, but they can really help many children.

Atropine is a medication that has been used for many years. It comes from a plant called deadly nightshade. Doctors have used it in different ways for decades. In eye care, it is often used to make pupils bigger during exams. At low doses, it can slow childhood myopia progression.

Doctors are still learning exactly how atropine works. It appears to affect parts of the eye that control the rate of eyeball growth. Myopia results from excessive growth of the eye. By slowing this growth, atropine helps keep your child’s prescription from getting stronger each year.

Why Low Dose Matters

Early studies used high doses of atropine, such as 1%. They worked well at slowing myopia, but they came with side effects. Children had trouble seeing up close because their pupils stayed too wide. They were also very sensitive to light.

Researchers then tried lower doses. The ATOM 2 study from Singapore compared 0.5%, 0.1%, and 0.01% atropine. They found that 0.01% slowed myopia almost as much as the higher doses, but with far fewer side effects. Children could still read easily and did not need special glasses or hats for light sensitivity.

More recent studies, such as the LAMP study from Hong Kong, have examined even finer differences. They found that 0.05% atropine may be more effective than 0.01%, though it carries a slightly higher risk of side effects. For many families, 0.01% strikes the right balance between effectiveness and comfort.

How It Is Used

Atropine eye drops are usually given once a day, at bedtime. They are easy to use, just like other eye drops. Most children use them for two to three years, but some may need them longer.

Regular checkups are important while using atropine. The eye doctor will check both your child’s prescription and the length of their eye. This helps determine whether the drops are working and whether any changes are needed.

When it is time to stop using atropine, doctors usually suggest reducing the drops slowly. Stopping all at once can make myopia get worse quickly. Gradually lowering the dose helps prevent this.

Who Is a Good Candidate?

Atropine is usually used for children whose myopia is getting worse quickly. If your child needs a stronger prescription every year, atropine may help slow this down. It is also helpful when other treatments do not work well. Some children cannot use contact lenses or have trouble with glasses. Atropine gives them another choice.

Age is important. Most studies focus on children between six and twelve years old, when myopia tends to get worse the fastest. Starting treatment early gives the best chance to slow it down before it gets too advanced.

Are There Side Effects?

At low doses, side effects are usually mild. Some children may notice a bit of light sensitivity or mild blurring when reading. These effects often get better as the eyes adjust over time.

Serious side effects are rare. But it is important to use the drops exactly as prescribed and keep up with follow-up visits. The eye doctor needs to monitor for any changes.

How It Compares to Other Treatments

Atropine is one of several options for managing myopia. It works differently from glasses or contact lenses. Glasses and contacts bend light to help you see clearly, but atropine works inside the eye to slow its growth. This means it can be used with other treatments. Some children use atropine along with special myopia-control contact lenses for extra help.

Studies suggest that combining treatments may be more effective than using just one. However, more research is needed to find out which combinations are best.

To learn more about atropine eye drops, visit the Vision Center of Lake Norman in Mooresville, North Carolina. You can call (704) 200-9477 to make an appointment.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12446493/

https://pubmed.ncbi.nlm.nih.gov/26350533/